Cargando…
Alectinib-induced rash unresponsive to desensitization: a case report and literature review
BACKGROUND: Since the inception of targeted therapies in treating lung cancer, providers have had to be aware of a new host of side effects when selecting management options for patients. Although targeted therapies are creating increased hope for patients with non-small cell lung cancers (NSCLC), u...
Autores principales: | Rodriguez, Robin Raquel, Dindak, Jessie, Kline, Janet, Raj, Moses S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349519/ https://www.ncbi.nlm.nih.gov/pubmed/37454087 http://dx.doi.org/10.1186/s12890-023-02558-6 |
Ejemplares similares
-
Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020) -
Drug rash induced by levothyroxine and oral desensitization
por: Dortas, Sérgio Duarte, et al.
Publicado: (2015) -
A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
por: Tamura, Tomoki, et al.
Publicado: (2023) -
Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature
por: Ramachandran, P, et al.
Publicado: (2018) -
Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report
por: Seki, Jack T., et al.
Publicado: (2017)